Peptide therapeutics: Targeting the undruggable space

被引:237
|
作者
Tsomaia, Natia [1 ]
机构
[1] Ipsen Biosci Inc, Compound Discovery, Cambridge, MA 02142 USA
关键词
Peptide therapeutics; Intracellular PPI; Undruggable targets; Peptide drugs; Stapling; Hydrogen bond surrogates; Beta-hairpin mimetics; Molecular grafting; Macrocyclization; IN-VITRO SELECTION; PASSIVE MEMBRANE-PERMEABILITY; PROTEIN-PROTEIN INTERACTIONS; MACROCYCLIC PEPTIDES; CYCLIC-PEPTIDES; ALPHA-HELIX; RIBOSOMAL SYNTHESIS; DRUG DISCOVERY; CYCLOSPORINE-A; SIDE-CHAIN;
D O I
10.1016/j.ejmech.2015.01.014
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Rapid advancements in genomics have brought a better understanding of molecular mechanisms for various pathologies and identified a number of highly attractive target classes. Some of these targets include intracellular protein protein interactions (PPIs), which control many essential biological pathways. Their surfaces are part of a diverse and unexplored biological space, where traditional small molecule scaffolds are not always successful. While large biologics can effectively modulate PPIs in the extracellular region, their limitation in crossing the cellular membrane leaves intracellular protein targets outside of their reach. There is a growing need in the pharmaceutical field to push the boundaries of traditional drug design and discover innovative molecules that are able to modulate key biological pathways by inhibiting intracellular PPIs. Peptides are one of the most promising classes of molecules that could deliver such therapeutics in the near future. In this review, we describe technological advancements and emerging chemical approaches for stabilizing active peptide conformations, including stapling, hydrogen bond surrogates, beta-hairpin mimetics, grafting on stable scaffolds, and macrocyclization. These design strategies carry the promise of opening the doors for peptide therapeutics to reach the currently "undruggable" space. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:459 / 470
页数:12
相关论文
共 50 条
  • [1] Targeting the undruggable
    Bakhoum, Samuel F.
    [J]. SCIENCE, 2023, 380 (6640) : 47A - 47B
  • [3] Strategies for targeting undruggable targets
    Zhang, Gong
    Zhang, Juan
    Gao, Yuting
    Li, Yangfeng
    Li, Yizhou
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (01) : 55 - 69
  • [4] Cell-based peptide screening to access the undruggable target space
    Hennemann, Hanjo
    Wirths, Sabine
    Carl, Claudia
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 94 : 489 - 496
  • [5] Therapeutic targeting of "undruggable" MYC
    Llombart, Victor
    Mansour, Marc R.
    [J]. EBIOMEDICINE, 2022, 75
  • [6] Nras in melanoma: Targeting the undruggable target
    Mandala, Mario
    Merelli, Barbara
    Massi, Daniela
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 92 (02) : 107 - 122
  • [7] Cancer Therapeutics Target the Undruggable, Confront Other Bugbears
    Shaffer, Catherine
    [J]. Genetic Engineering and Biotechnology News, 2022, 42 (05): : 46 - 48
  • [8] Targeting the undruggable: menin inhibitors ante portas
    Dempke, Wolfram C. M.
    Desole, Maximilian
    Chiusolo, Patrizia
    Sica, Simona
    Schmidt-Hieber, Martin
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 9451 - 9459
  • [9] Targeting the undruggable oncogenic KRAS: the dawn of hope
    Asimgil, Hande
    Ertetik, Utku
    Cevik, Nedim Can
    Ekizce, Menar
    Dogruoez, Alper
    Goekalp, Muazzez
    Arik-Sever, Elif
    Istvanffy, Rouzanna
    Friess, Helmut
    Ceyhan, Guralp Onur
    Demir, Ihsan Ekin
    [J]. JCI INSIGHT, 2022, 7 (01)
  • [10] Drugging the Undruggable: Advances on RAS Targeting in Cancer
    Molina-Arcas, Miriam
    Samani, Amit
    Downward, Julian
    [J]. GENES, 2021, 12 (06)